ASX speedo received on basis of combination of price and volume...

ASX speedo received on basis of combination of price and volume increase over past two days in absence of news.
HOWEVER
the reason I believe is because Amgen announced yesterday that their RAS inhibitor Ludakras got FDA approval on a paltry 124 patient phase 2 trial and a mere 36% response rate - and no survival data at all! Such is the enthusiasm and unmet need for RAS inhibitors.
Since PTX is well along the way in two phase one trials - with at least one observed response, even though this is not the object of phase one - a 124 patient phase 2 is a very likely proposition for this company. and hence it looks very cheap.
Given the volume entering I suspect this was insto money, maybe even overseas.
PTX missed the opportunity to educate the market about the AMGEN trial and the low hurdle needed to get FDA approval for these types of agents. Instead, it just replied "no" , "no," and no.
so the uneducated holders sold into the volume and we are back at open price. an ugly candle given the volume.